| 1 |
-
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching
-
6/11/2026 11:23:54 AM | Browse: 2 | Download: 10
|
| 2 |
-
Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies
-
2/6/2026 8:43:37 AM | Browse: 88 | Download: 242
|
| 3 |
-
Effect of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility during upper endoscopy in Asian patients with diabetes
-
12/15/2025 9:46:06 AM | Browse: 97 | Download: 426
|
| 4 |
-
Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study
-
11/14/2025 8:23:18 AM | Browse: 170 | Download: 513
|
| 5 |
-
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
-
11/14/2025 8:23:18 AM | Browse: 105 | Download: 484
|
| 6 |
-
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review
-
9/25/2025 3:33:08 AM | Browse: 192 | Download: 358
|
| 7 |
-
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
-
9/4/2025 7:48:03 AM | Browse: 554 | Download: 368
|
| 8 |
-
Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: A critical review of diagnostic, mechanistic, and therapeutic intersections
-
8/18/2025 10:04:52 AM | Browse: 169 | Download: 413
|
| 9 |
-
Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation
-
7/22/2025 8:44:58 AM | Browse: 161 | Download: 644
|
| 10 |
-
Beyond glycemic control: Roles of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease
-
6/13/2025 11:47:49 AM | Browse: 119 | Download: 519
|
| 11 |
-
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass
-
5/28/2025 7:32:57 AM | Browse: 194 | Download: 531
|
| 12 |
-
Is global interest in fasting, intermittent fasting and the liver shifting?
-
4/25/2025 8:22:58 AM | Browse: 115 | Download: 455
|
| 13 |
-
Efficacy of sodium−glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort
-
12/30/2024 9:47:23 AM | Browse: 300 | Download: 1107
|
| 14 |
-
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
-
11/29/2024 8:40:08 AM | Browse: 202 | Download: 569
|
| 15 |
-
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
-
10/31/2024 10:42:49 AM | Browse: 174 | Download: 536
|
| 16 |
-
Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes
-
10/16/2024 10:38:58 AM | Browse: 167 | Download: 565
|
| 17 |
-
Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases
-
9/20/2024 8:50:41 AM | Browse: 204 | Download: 601
|
| 18 |
-
Reconsidering the role of depression and common psychiatric disorders as partners in the type 2 diabetes epidemic
-
6/11/2024 2:35:35 PM | Browse: 387 | Download: 768
|
| 19 |
-
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon
-
2/4/2024 10:57:41 AM | Browse: 324 | Download: 1007
|
| 20 |
-
Effect of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
-
8/11/2023 11:04:23 AM | Browse: 332 | Download: 1367
|
| 21 |
-
Semaglutide-eye-catching results
-
4/12/2023 11:34:59 AM | Browse: 384 | Download: 1114
|
| 22 |
-
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
-
7/5/2022 1:22:29 AM | Browse: 579 | Download: 1386
|
| 23 |
-
Acute esophageal necrosis as a complication of diabetic ketoacidosis: A case report
-
10/29/2021 12:16:54 PM | Browse: 681 | Download: 1316
|
| 24 |
-
Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
-
9/7/2021 8:15:21 AM | Browse: 748 | Download: 1962
|
| 25 |
-
Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine
-
8/9/2021 10:25:22 AM | Browse: 718 | Download: 1646
|
| 26 |
-
Recent advances in new-onset diabetes mellitus after kidney transplantation
-
5/6/2021 11:18:51 AM | Browse: 708 | Download: 1670
|
| 27 |
-
Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
-
9/11/2020 7:11:20 AM | Browse: 825 | Download: 1681
|
| 28 |
-
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
-
8/25/2020 9:16:00 AM | Browse: 966 | Download: 2343
|
| 29 |
-
Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
-
11/27/2018 1:56:41 PM | Browse: 1240 | Download: 1999
|
| 30 |
-
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
-
10/11/2016 11:41:00 AM | Browse: 1544 | Download: 1824
|
| 31 |
-
Incretin-based therapies in prediabetes: Current evidence and future perspectives
-
12/13/2014 7:02:00 PM | Browse: 1544 | Download: 2337
|
| 32 |
-
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
-
10/29/2014 7:34:00 PM | Browse: 1280 | Download: 1992
|
| 33 |
-
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes
-
9/1/2014 12:00:00 PM | Browse: 1390 | Download: 1494
|
